Sell-off may continue, but don't panic
Sell-off may continue, but don't panic

Experts say that the recent market action feels 'more like a repositioning,' and that it won't stop anytime soon.

VIDEO ON MSN MONEY

The company's generics business is poised to grow after it recorded revenue of nearly $10 billion in 2010.

By Trefis Jan 9, 2012 10:10AM
CorbisPfizer (PFE) is the world's biggest pharmaceutical company and operates in two main segments: biopharmaceutical and diversified.

Biopharmaceutical includes primary care, specialty care, established products, emerging markets and oncology units that focus on treatment and prevention of cardiovascular and metabolic diseases, central nervous system disorders, arthritis and pain, respiratory diseases, urogenital conditions, cancer, eye disease and endocrine disorders, among others. Its diversified unit includes animal health, consumer health and nutritional products such as nutritional supplements and toddler formula products. 
Tags: PFE

Booming foreign interest in domestic reserves creates big opportunity.

By InvestorPlace Jan 9, 2012 9:56AM
Kevin Phillips/Digital Vision/age fotostockBy Aaron Levitt

The U.S. and Canada are sitting on one of the biggest energy booms ever. An oil and gas production renaissance is under way, thanks to improved hydraulic fracturing and advances in drilling techniques. Though not without controversy, shale formations like the Marcellus, Utica and Eagle Ford have become hotbeds of North American drilling activity because these advances have made it possible to extract the plethora of fossil fuels trapped between the rocks.


With billions of dollars in revenue at stake, these regions have witnessed a land grab not seen since the California Gold Rush of the 1800s. While the usual suspects like Exxon (XOM) are staking their claims, North America's shale interests are getting plenty of attention from overseas sources as well.

 

Positive action on new drugs by FDA in 2011 bodes well for biopharmaceuticals in 2012, and Celgene can offer long-term growth.

By Gene Marcial Jan 9, 2012 9:37AM
SuperStockIs the Food and Drug Administration becoming more of an ally than an obstacle to young biotech companies? Some analysts are starting to believe so. The FDA last year approved 30 new drugs, the highest yearly total since 2004, which industry watchers say represents very positive news for biotech companies.

 

"We see the FDA's modestly raised fiscal 2012 budget supporting continued improvement in the approval of new drugs on first review cycle," says Steven Silver, a biotech analyst at Standard & Poor's. The FDA's approval of new drugs in 2011 jumped 63% after an increase of about 50% in 2010, indicating a much-improved dedication by the FDA in supporting biotech and pharmaceutical companies in their quest for badly needed new drugs, Silver argues.

 
Tags: AMGNCELG

A recently launched oil and gas trust offers protected payouts and attractive yield.

By TheStockAdvisors Jan 8, 2012 6:03PM
Image: Oil Well Pumpjack © Roger Milley/Vetta/Getty ImagesThis post is one in a series in which more than 50 newsletter advisers share their Top Picks for 2012.

By Elliott Gue, The Energy Strategist

Chesapeake Granite Wash Trust (CHKR), the newest addition to the universe of U.S. oil and gas trusts, went public on Nov. 11.  It is also among the most promising and fastest-growing trusts in my coverage universe. 
Tags: CHKCHKR

Diversified holdings in utilities, commodities and transportation sectors offer stable cash flow.

By TheStockAdvisors Jan 8, 2012 3:29PM
Image: Elevated view of freight cars with coal © Joseph Sohm-Visions of America/Photodisc/Getty ImagesThis post is one in a series in which over 50 newsletter advisors share their Top Picks for 2012.

By Gordon Pape,
The Canada Report

This will be a year of uncertainty. Since I am a conservative investor by nature, I am selecting a security with limited downside risk, stable assets and good cash flow.  
Tags: BIP

The year has started off well, but some sectors and strategies have the potential to pay off even better in coming weeks.

By MoneyShow.com Jan 7, 2012 1:40AM

By Tom Aspray, MoneyShow.com


The first week of the New Year has certainly been a good one for the stock market, as the S&P 500 finished the week up 1.3% and the Dow Industrials gained 1.1%. This was in contrast to the 3.4% gain in the Nasdaq-100.


There was little in the way of bad news from the eurozone (for a change), though yields on many of the euro bonds are still at dangerously high levels. Upcoming bond auctions in euro land will be watched closely.

 

Major oil producers saw output reduced because of the natural decline in production fields, asset sales and political issues.

By Trefis Jan 6, 2012 6:14PM
Image: Oil derricks (© Comstock/Corbis)Overall, 2011 was a strong year for the oil industry, with almost all companies showing revenue and profit growth as a result of high crude prices.

Brent prices remained above the $100 per barrel mark for most of the year, driven by an improved economic outlook in the first half of the year and supply concerns in the second half. The year also saw the announcement that ConocoPhillips (COP) would divest its downstream business and focus on upstream exploration and production and unconventional resources such as shale. 
Tags: bpCOPCVX

Gold miner has production volume, growth projects and seasonal factors in its favor.

By TheStockAdvisors Jan 6, 2012 6:10PM
Image: Gold (© Comstock Images/Jupiterimages)This post is one in a series in which over 50 newsletter advisors share their Top Picks for 2012.

By Curtis Hesler, The Professional Timing Service

There was a study done in the 1970’s that revealed that gold stocks tended to bottom in the fourth quarter and rally strongly into the end of the first quarter of the next year. Thus, looking for seasonal bargains in the gold sector makes sense, especially now. 
Tags: goldIAG

After enjoying months of cheaper fuel, Americans will soon experience more pain at the pump because of oil speculation and market manipulation.

By Anthony Mirhaydari Jan 6, 2012 5:19PM

Image: Gas station © Purestock/Purestock/Getty ImagesThere have been a lot of "funny" things happening in the market over the past two months. I chalk it up to a combination of end-of-year seasonality and a desire by the powers that be to keep the market together long enough to exit ahead of the fall. Something similar happened in 2008 before the most acute phase of the bear market got started.

 

Wall Street has apparently been using large-cap energy stocks Exxon Mobil (XOM) and Chevron (CVX) to hold the Dow Jones industrial Average aloft, ostensibly to keep retail investors placated so the heavy hitters can create the little upward flurries they need to exit their position. (This has to do with the fact the Dow is a price-weighted index that can be pushed around by the most expensive stocks.)

 

Pause a moment before you start building an investment strategy based on fourth-quarter reports.

By Jim J. Jubak Jan 6, 2012 4:27PM
Image: Arrows (© Image Source Black/Getty)Fourth-quarter earnings season kicks off Monday with Alcoa (AA) reporting after the close.

This earnings season promises to be wild and very hard to interpret.

Let me start with the narrow Alcoa story and then expand to look at the earnings season as a whole.
 
Tags: AAaig

The storage market is rapidly changing in the age of big data and cloud computing.

By Trefis Jan 6, 2012 3:57PM
EMC (EMC) is the global leader in the disk storage system market as well as the storage software market. However, the stock has fallen from highs of around $30 during the middle of 2011 to trade Friday at $22.

Even NetApp (NTAP), EMC's only major pureplay storage competitor, saw its stock tumble in the second half of 2011 largely due to concerns of lower government and enterprise spending as the macroeconomic condition deteriorated in the U.S. and Europe. 
Tags: EMCHPQibm

The biggest letdown is still under the hood.

By Motley Fool Pick of the Day Jan 6, 2012 3:12PM

Image: Los Angeles, Calif., traffic on Interstate 405 © VisionsofAmerica/Joe Sohm/Digital Vision/Getty ImagesBy Alex Planes

 

Electric cars started 2011 with a lot of hype and ended the year with a big face-plant. Combined sales for the plug-in electric movement's marquee names, General Motors' (GM) Chevy Volt and the Nissan Leaf, clocked in at fewer than 20,000 units. IDC Energy Insights predicted that half a million plug-ins would sell in 2011, which now seems downright silly.

 

Don't worry, IDC. You're far from the first to get burned by your love of the electric car.

 

Sabrient Systems has a strong track record, which is why its annual 'Baker's Dozen' list is getting attention.

By Kim Peterson Jan 6, 2012 2:18PM
Image: Arrow Up (© Nicholas Monu/iStock Exclusive/Getty Images)Sure, it's fine to pick stocks using philosophical models and what-would-Buffett-do theories, but you know how Wall Street does it? With computers and algorithms. Data mining. Statistical arbitrage.

Stuff you and I could never fathom.

So when one of the more respected quantitative investment shops releases its stock picks, people pay attention. And when that investment shop becomes known for beating the market year after year with those picks -- well, a lot of people pay attention. 

Technical methods identified the strongest and weakest sectors last year, and now they predict the best buying opportunities ahead.

By MoneyShow.com Jan 6, 2012 1:58PM

Image: Stock index © Image Source/Getty ImagesBy Tom Aspray, MoneyShow.com


The sector performance in 2011 further illustrates the year’s volatility. Many sectors had a few strong quarters, but the yearly performance numbers do not reflect the wide price swings.


Since the S&P 500 and its tracking exchange-traded fund (ETF) Spyder Trust (SPY) were essentially flat for the year, all the other Select Sector SPDR ETFs, except for Financials (XLF), Materials (XLB), and Industrials (XLI), performed better.

 

Treatments for myelofibrosis and arthritis could make biotech a takeover target for Big Pharma.

By TheStockAdvisors Jan 6, 2012 1:56PM
Image: Pills (© Digital Vision Ltd./SuperStock/SuperStock)This post is one in a series in which over 50 newsletter advisors share their Top Picks for 2012.

By John McCamant, The Medical technology Stock Letter

Incyte (INCY) is our top stock selection for 2012.  The Delaware company is a leader in developing small molecule drugs for cancer and inflammation.   
Tags: INCY

DATA PROVIDERS

Copyright © 2014 Microsoft. All rights reserved.

Fundamental company data and historical chart data provided by Morningstar Inc. Real-time index quotes and delayed quotes supplied by Morningstar Inc. Quotes delayed by up to 15 minutes, except where indicated otherwise. Fund summary, fund performance and dividend data provided by Morningstar Inc. Analyst recommendations provided by Zacks Investment Research. StockScouter data provided by Verus Analytics. IPO data provided by Hoover's Inc. Index membership data provided by Morningstar Inc.

STOCK SCOUTER

StockScouter rates stocks from 1 to 10, with 10 being the best, using a system of advanced mathematics to determine a stock's expected risk and return. Ratings are displayed on a bell curve, meaning there will be fewer ratings of 1 and 10 and far more of 4 through 7.

124
124 rated 1
279
279 rated 2
471
471 rated 3
714
714 rated 4
642
642 rated 5
604
604 rated 6
614
614 rated 7
450
450 rated 8
303
303 rated 9
115
115 rated 10
12345678910

Top Picks

SYMBOLNAMERATING
ARCPAMERICAN REALTY CAPITAL PROPERTIES Inc10
BIDUBAIDU Inc10
CITCIT GROUP Inc NEW10
HPQHEWLETT PACKARD CO10
ITUBITAU UNIBANCO BANCO MULTIPLO S.A.10
More

Trending NOW

What’s this?

RECENT QUOTES

WATCHLIST

Symbol
Last
Change
Shares
Quotes delayed at least 15 min

ABOUT

Top Stocks provides analysis about the most noteworthy stocks in the market each day, combining some of the best content from around the MSN Money site and the rest of the Web.

Contributors include professional investors and journalists affiliated with MSN Money.

Follow us on Twitter @topstocksmsn.

MARKET UPDATE

NAMELASTCHANGE% CHANGE
There’s a problem getting this information right now. Please try again later.
NAMELASTCHANGE% CHANGE
There’s a problem getting this information right now. Please try again later.
Market index data delayed by 15 minutes

[BRIEFING.COM] The stock market finished a down week on a cautious note with small caps leading the retreat. The Russell 2000 lost 0.5%, widening its weekly decline to 2.6%, while the S&P 500 shed 0.3%. The benchmark index ended the week lower by 2.7%.

This morning, the market was provided a basis to rebound with the July employment report, which was just right for the policy doves (209K versus Briefing.com consensus 220K). It showed payroll growth that was weaker than expected, ... More


Currencies

NAMELASTCHANGE% CHANGE
There’s a problem getting this information right now. Please try again later.